Key result
Atherosclerosis and prostate cancer share common pathogenic mechanisms, with hypercholesterolemia contributing to cancer progression and statin therapy potentially reducing the risk of disease development and progression.
Why the study?
Most patients with prostate cancer die from cardiovascular diseases rather than cancer, and emerging studies suggest a stronger relationship between atherosclerosis and prostate cancer than previously thought.
Does cardiovascular risk management, including statins, reduce the risk of prostate cancer progression and cardiovascular events in patients with prostate cancer?
Does cardiovascular risk management, including statins, reduce the risk of prostate cancer progression and cardiovascular events in patients with prostate cancer?
Shared mechanisms between atherosclerosis and prostate cancer emphasize the need for comprehensive cardiovascular risk assessment and management, including statin therapy, in prostate cancer patients.
Supports statin investigation in prostate cancer but should not change practice; leaves open randomized confirmation.
Cardiovascular disease and cancer remain the leading causes of hospitalization and death worldwide. Prostate cancer (PC) is one of the most common malignant diseases in men. Epidemiological studies have shown that the majority of patients with PC die not from cancer but from cardiovascular diseases, particularly coronary heart disease. In recent years, several studies have examined the relationship between atherosclerosis and PC, suggesting a stronger relationship than previously thought. Processing characteristics of the development and progression of both diseases include dysregulation of cell proliferation, oxidative stress, genetic changes, and inflammation. Despite conflicting data on the role of high cholesterol levels in the development of PC over the past decade, numerous studies have confirmed its importance in PC development and progression; meanwhile, statins have confirmed their value in reducing the risk of disease development and progression. The presented data confirm the need for a thorough assessment of cardiovascular risk factors, the presence of concomitant cardiovascular diseases in patients with PC, and the use of methods for the prevention and treatment of diseases associated with atherosclerosis to reduce cardiovascular risk and inhibit PC progression.
No takes yet. Share an insight, caveat, or question.
Помешкина et al. (2023) conducted a review in Prostate cancer and atherosclerosis. Atherosclerosis, hypercholesterolemia, and statin use was evaluated. Atherosclerosis and prostate cancer share common pathogenic mechanisms, with hypercholesterolemia contributing to cancer progression and statin therapy potentially reducing the risk of disease development and progression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: